Willem J.S. De Villiers

Prof. Willem J.S. De Villiers

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
TDTanja A. Davis
Tanja A. Davis
DCDaleen Conradie
Daleen Conradie
PSPreetha Shridas
Preetha Shridas
FBFrederick C. de Beer
Frederick C. de Beer
AEAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
WVWillem J.S. De Villiers
Willem J.S. De Villiers
Identifying new approaches to lessen inflammation, as well as the associated malignant consequences, remains crucial to improving the lives and prognosis of patients diagnosed with inflammatory bowel diseases. While it has previously been suggested as a suitable biomarker for monitoring disease activity in patients diagnosed with Crohn's disease, the role of the acute-phase protein serum amyloid A (SAA) in inflammatory bowel disease remains unclear. In this study, we aimed to assess the role of SAA in colitis-associated cancer. We established a model of colitis-associated cancer in wild-type and SAA double-knockout (Saa1/2-/-) mice by following the azoxymethane/dextran sulfate sodium protocol. Disease activity was monitored throughout the study while colon and tumour tissues were harvested for subsequent use in cytokine analyses, western blot and immunohistochemistry experiments. We observed attenuated disease activity in mice deficient for Saa1/2 as evidenced by decreased weight loss, increased stool consistency, decreased rectal bleeding and decreased colitis-associated tissue damage. Macrophage infiltration, including CD206+ M2-like macrophages, was also attenuated in SAA knockout mice, while levels of IL-4, IL-10 and TNF-ɑ was decreased in the distal colon. Mice deficient for SAA also displayed a decreased tumour burden, and tumours were found to have increased apoptotic activity coupled with decreased expression for markers of proliferation. Based on these findings, we conclude that SAA has an active role in inflammatory bowel disease and that it could serve as a therapeutic target aimed at decreasing chronic inflammation and the associated risk of developing colitis-associated cancer.

1 December 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GWGreta M de Waal
Greta M de Waal
WVWillem J.S. De Villiers
Willem J.S. De Villiers
EPEtheresia Pretorius
Etheresia Pretorius
: There is a causal relationship between cancer (including colorectal cancer), chronic systemic inflammation and persistent infections, and the presence of dysregulated circulating inflammatory markers. It is known that aberrant clot formation and coagulopathies occur in systemic inflammation. In colorectal cancer, there is close link between gut dysbiosis and an inflammatory profile. In this review we present evidence of the connection between gut dysbiosis, the entry of bacteria into the internal environment and the presence of their highly potent inflammagenic molecules, such as lipopolysaccharide and lipoteichoic acid, in circulation. These bacterial components may act as one of the main drivers of the inflammatory process (including hypercoagulation) in colorectal cancer. We review literature that points to the role of these bacterial inflammagens and how they contribute to colorectal carcinogenesis. Insight into the factors that promote carcinogenesis is crucial to effectively prevent and screen for colorectal cancer. Early diagnosis of an activated coagulation system and the detection of bacterial components in circulation and also in the tumour microenvironment, could therefore be important, and may also, together with modulation of the gut microbiota, serve as potential therapeutic targets.

23 August 2024 in Biology
Verified
Journal Article
Open access
PDF file
DODaniel Wilhelm Olivier
Daniel Wilhelm Olivier
CECarla Eksteen
Carla Eksteen
MPManisha du Plessis
Manisha du Plessis
LJLouis De Jager
Louis De Jager
LELize Engelbrecht
Lize Engelbrecht
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Background: Previous research has shown that the Serum Amyloid A (SAA) protein family is intricately involved in inflammatory signaling and various disease pathologies. We have previously demonstrated that SAA is associated with increased colitis disease severity and the promotion of tumorigenesis. However, the specific role of SAA proteins in breast cancer pathology remains unclear. Therefore, we investigated the role of systemic SAA1 and SAA2 (SAA1/2) in a triple-negative breast cancer mouse model. Methods: Syngeneic breast tumors were established in wild-type mice, and mice lacking the SAA1/2 (SAADKO). Subsequently, tumor volume was monitored, species survival determined, the inflammatory profiles of mice assessed with a multiplex assay, and tumor molecular biology and histology characterized with Western blotting and H&E histological staining. Results: WT tumor-bearing mice had increased levels of plasma SAA compared to wild-type control mice, while SAADKO control and tumor-bearing mice presented with lower levels of SAA in their plasma. SAADKO tumor-bearing mice also displayed significantly lower concentrations of systemic inflammatory markers. Tumors from SAADKO mice overall had lower levels of SAA compared to tumors from wild-type mice, decreased apoptosis and inflammasome signaling, and little to no tumor necrosis. Conclusions: We demonstrated that systemic SAA1/2 stimulates the activation of the NLRP3 inflammasome in breast tumors, leading to the production of pro-inflammatory cytokines. This, in turn, promoted apoptosis and tumor necrosis but did not significantly impact tumor growth or histological grading.

30 September 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
GNGustav van Niekerk
Gustav van Niekerk
TDTanja Davis
Tanja Davis
WVWillem J.S. De Villiers
Willem J.S. De Villiers
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Nutritional support continues to receive much attention as a possible intervention to prevent loss of lean tissue mass, promote recovery and re-establish proper immune function in critical care patients. Yet there remains much controversy regarding the clinical efficacy of such interventions. In addition to the direct effect of nutrition in terms of micro- and macronutrient content, nutritional formulations may exert an effect via the physiological response to feeding. Here, we highlight the key role of postprandial reabsorbed bile acids in attenuating both the inflammatory response and autophagy. These observations suggest that not all patients would benefit from aggressive nutritional support.